Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions

Frederic Castinetti 1, 2, 3, * Frédéric Albarel 1, 3, 2 Françoise Archambeaud 4 Jérôme Bertherat 5, 6 Benjamin Bouillet 7, 8 Perrine Buffier 7 Claire Briet 9, 10, 11 Bertrand Cariou 12, 13 Ph. Caron 14 Olivier Chabre 15 Philippe Chanson 16, 17 Christine Cortet 18 Christine Do Cao 18 Delphine Drui 13, 12 Magali Haissaguerre 19, 20 Ségolène Hescot 21 Frédéric Illouz 22 Emmanuelle Kuhn 17, 16 Najiba Lahlou Emilie Merlen 18 Véronique Raverot 23 Sarra Smati 12, 13 Bruno Vergès 7, 8 Françoise Borson-Chazot 24, 25
* Auteur correspondant
Abstract : The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects.
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01979955
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : lundi 14 janvier 2019 - 09:41:34
Dernière modification le : mardi 13 juillet 2021 - 16:28:02

Identifiants

Citation

Frederic Castinetti, Frédéric Albarel, Françoise Archambeaud, Jérôme Bertherat, Benjamin Bouillet, et al.. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions. Annales d'Endocrinologie, Elsevier Masson, 2018, 79 (5), pp.591-595. ⟨10.1016/j.ando.2018.07.005⟩. ⟨hal-01979955⟩

Partager

Métriques

Consultations de la notice

648